The emergence of multidrug resistanceagainst several antifungal drugs and the absence of alternate therapy limits the treatment choices leading to the spread of Candida auris infections, especially inimmunocompromised patients. This work aims to construct the multi-epitope vaccine using an immuno-informatics approachdue to the lack of efficient treatments for C. auris. Very few in-silico studies have been conducted to design a vaccine against C. auris majorly targeting the specific proteins regardless of the importance of non-structural proteins. The whole proteome was targeted to identify the antigenic proteins because components other than non-structural proteins can also potentially act as immunogens. The antigenic determinants were mapped in the target proteins and screened via IEDB analysis and prediction tools. Distinctive HLA types manifested at varied genotypic frequencies in diverse ethnicities. Therefore, to design an effectual vaccine construct, the candidate T-cell antigenic determinants were employed for population coverage. Various bioinformatics tools and servers were used for the 3D analysis of vaccine structure, including prediction, refinement, and validation. The computational validation of the molecular interaction of the proposed vaccine with TLR4, TLR5, HLA-A*11:01, and HLA-A*02:01 was done using docking studies. The docked complexes were subjected to molecular dynamics (MD) simulations to confirm their stability, compactness, and flexibility. Simulation studies demonstrated that the vaccine complexed with immune and MHC receptors was stable during the simulation time. The outcome of the current study suggests the designed vaccine can be a potential vaccine candidate and elicit the immune response against C. auris. However, experimental verification (in-vitro/in-vivo) is required to confirm the effectiveness and safety of the designed vaccine construct.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgeb.2025.100474DOI Listing

Publication Analysis

Top Keywords

vaccine
10
candida auris
8
non-structural proteins
8
antigenic determinants
8
vaccine construct
8
designed vaccine
8
auris
5
proteins
5
designing multi-valent
4
multi-valent epitope
4

Similar Publications

Objective: To review several behavioral economics-based interventions ("healthy nudges") aimed at mitigating the overuse and underuse of healthcare resources -phenomena associated with poorer health outcomes and increased costs.

Method: A comparative case study approach is used to assess the effectiveness of ten studies designed to improve treatment adherence and prevent underuse, as well as those focused on improving prescribing practices to address overuse.

Results: First, healthy nudges are generally effective, although there is considerable variability in their outcomes.

View Article and Find Full Text PDF

Community pharmacy services in the late COVID-19 period: What has driven change?

Res Social Adm Pharm

March 2025

WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute), Stubenring 6, 1010, Vienna, Austria; Department of Health Policy, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK. Electronic address:

Background: Community pharmacy appears to have undergone considerable change over the years.

Objectives: The objective of this research is to study the range of community pharmacy services provided in late stages of the COVID-19 pandemic and during the last decades and to identify potential drivers for change.

Methods: Four European countries (Austria, England, Estonia, and Portugal), which represent a balance in terms of income, organization of the health system and pharmacy services, were selected as case studies.

View Article and Find Full Text PDF

Introduction: As of 24 October 2021, 128,868 laboratory-confirmed COVID-19 cases and 3550 deaths were reported from Namibia. The national COVID-19 vaccination campaign that started in March 2021 included health workers (HWs) as a priority group. The vaccines most administered were Sinopharm, AstraZeneca, Pfizer-BioNtech, and Janssen.

View Article and Find Full Text PDF

Author's reply: "Navigating anti-TNF therapy risks: Real-world insights on pregnancy, breastfeeding, and vaccines in IBD patients".

Dig Liver Dis

March 2025

Université Clermont Auvergne, Inserm, CHU Clermont-Ferrand, 3iHP, Service d'Hépato-Gastro Entérologie, Clermont-Ferrand, France; Université Clermont Auvergne, 3iHP, Inserm U1071, M2iSH, USC-INRA 2018, F-63000 Clermont-Ferrand, France. Electronic address:

View Article and Find Full Text PDF

Delayed inflammatory nodules (DIN) after soft-tissue filler injection may occur after infections, vaccinations, or procedures. We report a DIN from predominantly low-molecular-weight HA (PLMW-HA) filler secondary to COVID-19 infection that was resistant to conservative management, requiring intralesional combination therapy with triamcinolone, 5-fluorouracil, and recombinant human hyaluronidase for resolution.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!